In addition to advocating TRPS1 as a new target for the development of chemosensitizers for BC, our data provide evidence for the beneficial effect of clinically approved PARP inhibitor drugs in the treatment of chemo-refractory BC with elevated TRPS1, thus providing a ready-to-use pharmacological approach to overcome chemo-failure in patients with BC. This evidence concerns the gene PARP1 and breast cancer.